218 related articles for article (PubMed ID: 7913311)
41. Clinical relevance of P-glycoprotein expression in haematological malignancies.
Nooter K; Sonneveld P
Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
[TBL] [Abstract][Full Text] [Related]
42. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
43. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
44. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
45. Multidrug resistance (MDR) genes in haematological malignancies.
Nooter K; Sonneveld P
Cytotechnology; 1993; 12(1-3):213-30. PubMed ID: 7765326
[TBL] [Abstract][Full Text] [Related]
46. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines.
van der Pol JP; Blom DJ; Flens MJ; Luyten GP; de Waard-Siebinga I; Koornneef L; Scheper RJ; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Nov; 38(12):2523-30. PubMed ID: 9375571
[TBL] [Abstract][Full Text] [Related]
47. Genetics of drug resistance.
Biedler JL; Spengler BA
Cancer Treat Res; 1994; 73():1-16. PubMed ID: 7710901
[No Abstract] [Full Text] [Related]
48. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
49. Genetic aspects of multidrug resistance.
Biedler JL
Cancer; 1992 Sep; 70(6 Suppl):1799-809. PubMed ID: 1355404
[TBL] [Abstract][Full Text] [Related]
50. Probing the interaction of the multidrug-resistance phenotype with the polypeptide ionophore gramicidin D via functional channel formation.
Assaraf YG; Borgnia MJ
Eur J Biochem; 1994 Jun; 222(3):813-24. PubMed ID: 7517866
[TBL] [Abstract][Full Text] [Related]
51. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
[TBL] [Abstract][Full Text] [Related]
52. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
Minderman H; Brooks TA; O'Loughlin KL; Ojima I; Bernacki RJ; Baer MR
Cancer Chemother Pharmacol; 2004 May; 53(5):363-9. PubMed ID: 15060738
[TBL] [Abstract][Full Text] [Related]
53. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
54. [A molecular basis for multidrug-resistance and reversal of resistance with human malignant cells].
Akiyama S; Kikuchi H; Yoshimura A; Matsumoto M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2617-25. PubMed ID: 2888434
[TBL] [Abstract][Full Text] [Related]
55. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.
Litman T; Druley TE; Stein WD; Bates SE
Cell Mol Life Sci; 2001 Jun; 58(7):931-59. PubMed ID: 11497241
[TBL] [Abstract][Full Text] [Related]
56. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis.
Kim R; Ohi Y; Inoue H; Aogi K; Toge T
Anticancer Res; 1999; 19(3A):1779-83. PubMed ID: 10470115
[TBL] [Abstract][Full Text] [Related]
57. Topoisomerase II in multiple drug resistance.
Hofmann GA; Mattern MR
Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
[TBL] [Abstract][Full Text] [Related]
58. Multidrug resistance and P-glycoprotein expression in human cancer.
Ma DD; Bell DR
Aust N Z J Med; 1989 Dec; 19(6):736-43. PubMed ID: 2576624
[No Abstract] [Full Text] [Related]
59. Functional studies with a full-length P-glycoprotein cDNA encoded by the hamster pgp1 gene.
Devine SE; Melera PW
Cancer Chemother Pharmacol; 1994; 33(6):465-71. PubMed ID: 7907953
[TBL] [Abstract][Full Text] [Related]
60. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
Hait WN; Yang JM
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
